electroCore (ECOR) reported a record quarterly revenue of $9.6 million for Q1 2026, marking a 43% year-over-year increase, driven primarily by a 48% rise in VA prescription device revenue. The company achieved an impressive gross margin of 87%, reflecting a 200 basis point improvement, while its adjusted EBITDA loss narrowed by 24% to $2.3 million, despite incurring $1.9 million in leadership transition costs.
This strong performance underscores the company’s strategic focus on deepening its penetration within the Veterans Affairs market, where only 2.5% of the addressable headache market has been tapped. Management highlighted growth opportunities in both the VA and Department of Defense channels, supported by a substantial underlying patient population dealing with chronic pain and PTSD. The consumer wellness segment also saw revenue increase by 44%, driven by effective advertising strategies.
Looking ahead, electroCore reaffirmed its 2026 revenue guidance of approximately 30% growth, indicating confidence in its operational strategy and market potential. For investors, the combination of expanding margins and a clear path to profitability makes electroCore an intriguing prospect in the healthcare technology space.
Source: fool.com